Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
Giuseppe Della Pepa, Marco Russo, Marilena Vitale, Fabrizia Carli, Claudia Vetrani, Maria Masulli, Gabriele Riccardi, Olga Vaccaro, Amalia Gastaldelli, Angela A. Rivellese, Lutgarda Bozzetto
Topics & Concepts
PioglitazoneMedicineType 2 diabetesDiabetes mellitusInternal medicineSubgroup analysisPathophysiologyClinical trialRandomized controlled trialGastroenterologyEndocrinologyMeta-analysisLiver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug-Induced Hepatotoxicity and Protection